Functions of mammalian Smad genes as revealed by targeted gene disruption in mice

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 49-58

  Weinstein, Michael ^a   Yang, Xiao ^a   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Angiogenesis; Cancer; Embryo; Immunity; Smads

Indexed keywords

DNA BINDING PROTEIN; NODAL PROTEIN; PHOSPHOPROTEIN; PROTEIN SMAD3; SMAD PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DEVELOPMENT; CANCER INCIDENCE; CRANIOFACIAL MALFORMATION; FETUS DEVELOPMENT; GASTRULA; GASTRULATION; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HAPLOTYPE; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; LIVER; LIVER DEVELOPMENT; MAMMAL; METABOLISM; MOUSE; MOUSE MUTANT; MUCOSAL IMMUNITY; MULTIGENE FAMILY; MUTAGENESIS; NEOPLASM; NONHUMAN; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SITUS INVERSUS; STOMACH CANCER; TUMOR SUPPRESSOR GENE; WOUND HEALING;

ANIMALS; BONE DEVELOPMENT; DNA-BINDING PROTEINS; EMBRYONIC AND FETAL DEVELOPMENT; GASTRULA; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNE SYSTEM; LIVER; MAMMALS; MICE; MICE, KNOCKOUT; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHOPROTEINS; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

ANIMALIA; MAMMALIA; RODENTIA;

EID: 0034023371     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00028-3     Document Type: Review

References (75)

1. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73:1995;333-346.
2. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8:1997;21-43.
3. de Visser K.E., Kast W.M. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia. 13:1999;1188-1199.
4. Lee C., Sintich S.M., Mathews E.P., Shah A.H., Kundu S.D., Perry K.T., et al. Transforming growth factor-beta in benign and malignant prostate. Prostate. 39:1999;285-290.
5. Akhurst R.J., Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J. Pathol. 187:1999;82-90.
6. Wrana J.L., Carcamo J., Attisano L., Cheifetz S., Zentella A., Lopez-Casillas F., Massague J. The type II TGF-beta receptor signals diverse responses in cooperation with the type I receptor. Cold Spring Harb. Symp. Quant. Biol. 57:1992;81-86.
7. Letsou A., Arora K., Wrana J.L., Simin K., Twombly V., Jamal J., et al. Drosophila Dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGF beta receptor family. Cell. 80:1995;899-908.
8. Ruberte E., Marty T., Nellen D., Affolter M., Basler K. An absolute requirement for both the type II and type I receptors, punt and thick veins, for dpp signaling in vivo. Cell. 80:1995;889-897.
9. Derynck R., Gelbart W.M., Harland R.M., Heldin C.H., Kern S.E., Massague J., et al. Nomenclature: vertebrate mediators of TGFbeta family signals. Cell. 87:1996;173.
10. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
11. Massague J. TGF-beta signal transduction. Ann. Rev. Biochem. 67:1998;753-791.
12. Zhang D., Jacobberger J.W. TGF-beta 1 perturbation of the fibroblast cell cycle during exponential growth: switching between negative and positive regulation. Cell Prolif. 29:1996;289-307.
13. Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16:1997;5353-5362.
14. Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:1996;543-552.
15. Macias-Silva M., Abdollah S., Hoodless P.A., Pirone R., Attisano L., Wrana J.L. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1996;1215-1224.
16. Graff J.M., Bansal A., Melton D.A. Xenopus Mad proteins transduce distinct subsets of signals for the TGF beta superfamily. Cell. 85:1996;479-487.
17. Kretzschmar M., Liu F., Hata A., Doody J., Massague J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11:1997;984-995.
18. Lagna G., Hata A., Hemmati-Brivanlou A., Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature. 383:1996;832-836.
19. Zhang Y., Feng X., We R., Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature. 383:1996;168-172.
20. Kawabata M., Imamura T., Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 9:1998;49-61.
21. Suzuki A., Chang C., Yingling J.M., Wang X.F., Hemmati-Brivanlou A. Smad5 induces ventral fates in Xenopus embryo. Dev. Biol. 184:1997;402-405.
22. Liu F., Hata A., Baker J.C., Doody J., Carcamo J., Harland R.M., Massague J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature. 381:1996;620-623.
23. Nakayama T., Snyder M.A., Grewal S.S., Tsuneizumi K., Tabata T., Christian J.L. Xenopus Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. Development. 125:1998;857-867.
24. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.Y., Grinnell B.W., et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell. 89:1997;1165-1173.
25. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 389:1997;631-635.
26. Hata A., Lagna G., Massague J., Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 12:1998;186-197.
27. Tam P.P., Behringer R.R. Mouse gastrulation: the formation of a mammalian body plan. Mech. Dev. 68:1997;3-25.
28. Hogan BL, Blessing M, Winnier GE, Suzuki N, Jones CM. Growth factors in development: The role of TGF-beta related polypeptide signalling molecules in embryogenesis. Dev Suppl 1994;53-60
29. Weinstein M., Yang X., Li C., Xu X., Gotay J., Deng C.X. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor Smad2. Proc. Natl. Acad. Sci. USA. 95:1998;9378-9383.
30. Nomura M., Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature. 393:1998;786-790.
31. Varlet I., Collignon J., Robertson E.J. Nodal expression in the primitive endoderm is required for specification of the anterior axis during mouse gastrulation. Development. 124:1997;1033-1044.
32. Iannaccone P.M., Zhou X., Khokha M., Boucher D., Kuehn M.R. Insertional mutation of a gene involved in growth regulation of the early mouse embryo. Dev. Dyn. 194:1992;198-208.
33. Conlon F.L., Lyons K.M., Takaesu N., Barth K.S., Kispert A., Herrmann B., Robertson E.J. A primary requirement for nodal in the formation and maintenance of the primitive streak in the mouse. Development. 120:1994;1919-1928.
34. Waldrip W.R., Bikoff E.K., Hoodless P.A., Wrana J.L., Robertson E.J. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell. 92:1998;797-808.
35. Gu Z., Reynolds E.M., Song J., Lei H., Feijen A., Yu L., et al. The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development. 126:1999;2551-2561.
36. Gu Z., Nomura M., Simpson B.B., Lei H., Feijen A., van den Eijnden-van Raaij J., et al. The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. Genes Dev. 12:1998;844-857.
37. Yang X., Li C., Xu X., Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. USA. 95:1998;3667-3672.
38. Sirard C., de la Pompa J.L., Elia A., Itie A., Mirtsos C., Cheung A., et al. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev. 12:1998;107-119.
39. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
40. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 285:1999;1926-1928.
41. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
42. Chang H., Huylebroeck D., Verschueren K., Guo Q., Matzuk M.M., Zwijsen A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development. 126:1999;1631-1642.
43. Yang X., Castilla L.H., Xu X., Li C., Gotay J., Weinstein M., et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development. 126:1999;1571-1580.
44. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 121:1995;1845-1854.
45. Goumans M.J., Zwijsen A., van Rooijen M.A., Huylebroeck D., Roelen B.A., Mummery C.L. Transforming growth factor-beta signalling in extraembryonic mesoderm is required for yolk sac vasculogenesis in mice. Development. 126:1999;3473-3483.
46. Bruno E., Horrigan S.K., Van Den Berg D., Rozler E., Fitting P.R., Moss S.T., et al. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood. 91:1998;1917-1923.
47. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis? Cell. 87:1996;1153-1155.
48. Datto M.B., Frederick J.P., Pan L., Borton A.J., Zhuang Y., Wang X.F. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell Biol. 19:1999;2495-2504.
49. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18:1999;1280-1291.
50. Ashcroft G.S., Yang X., Glick A., Weinstein M., Letterio J.J., Mizel D.E., et al. Mice lacking SMAD 3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biology. 1:1999;260-266.
51. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 400:1999;687-693.
52. Bonyadi M., Rusholme S.A., Cousins F.M., Su H.C., Biron C.A., Farrall M., Akhurst R.J. Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat. Genet. 15:1997;207-211.
53. Zhao M., Zimmermann A. Liver cell dysplasia: reactivities for c-met protein, Rb protein, E- cadherin and transforming growth factor-beta 1 in comparison with hepatocellular carcinoma. Histol. Histopathol. 13:1998;657-670.
54. Bedossa P., Peltier E., Terris B., Franco D., Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology. 21:1995;760-766.
55. Anscher M.S., Peters W.P., Reisenbichler H., Petros W.P., Jirtle R.L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N. Engl. J. Med. 328:1993;1592-1598.
56. Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Terashima M., et al. Allelotype of adenoma and differentiated adenocarcinoma of the stomach. J. Pathol. 180:1996;371-377.
57. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
58. Howe J.R., Ringold J.C., Summers R.W., Mitros F.A., Nishimura D.Y., Stone E.M. A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am. J. Hum. Genet. 62:1998;1129-1136.
59. Hahn S.A., Hoque A.T., Moskaluk C.A., da Costa L.T., Schutte M., Rozenblum E., et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 56:1996;490-494.
60. Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., et al. DPC4 gene in various tumor types. Cancer Res. 56:1996;2527-2530.
61. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;2718-2720.
62. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:1998;1086-1088.
63. Friedl W., Kruse R., Uhlhaas S., Stolte M., Schartmann B., Keller, et al. Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients. Genes Chromosomes Cancer. 25:1999;403-406.
64. Takaku K., Oshima M., Miyoshi H., Matsui M., Seldin M.F., Taketo M.M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 92:1998;645-656.
65. Oshima M., Oshima H., Kitagawa K., Kobayashi M., Itakura C., Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl. Acad. Sci. USA. 92:1995;4482-4486.
66. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:1998;4657-4667.
67. Zhu Y., Richardson J.A., Parada L.F., Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.
68. Lo R.S., Chen Y.G., Shi Y., Pavletich N.P., Massague J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J. 17:1998;996-1005.
69. Chen X., Rubock M.J., Whitman M. A transcriptional partner for MAD proteins in TGF-beta signalling. Nature. 383:1996;691-696.
70. Shen X., Hu P.P., Liberati N.T., Datto M.B., Frederick J.P., Wang X.F. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol. Biol. Cell. 9:1998;3309-3319.
71. Li J., Tsuji K., Komori T., Miyazono K., Wrana J.L., Ito Y., et al. Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells. J. Biol. Chem. 273:1998;31009-31015.
72. Song C.Z., Siok T.E., Gelehrter T.D. Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J. Biol. Chem. 273:1998;29287-29290.
73. Chen X., Weisberg E., Fridmacher V., Watanabe M., Naco G., Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature. 389:1997;85-89.
74. Yingling J.M., Datto M.B., Wong C., Frederick J.P., Liberati N.T., Wang X.F. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol. Cell Biol. 17:1997;7019-7028.
75. Dennier S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.-M. Direct binding of Smad3 and Smad4 to critical TGFbeta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:1998;3091-3100.